文献速递中医儿科中药与中成药合理使用中医内科

克敏胶囊通过调控PI3K/AKT信号通路及TRPA1/TRPV1通道改善感染后咳嗽

Kemin capsule ameliorates post-infectious cough by modulating the PI3K/AKT signaling pathway and TRPA1/TRPV1 channels.
PubMed 文献 · J Ethnopharmacol · 2024-09-19

本研究结合UPLC-MS、生物信息学、网络药理学与分子对接,并通过RSV诱导的Balb/c小鼠PIC模型及A549细胞实验,探究克敏胶囊治疗感染后咳嗽的机制。结果显示克敏胶囊可减少咳嗽频率、延长咳嗽潜伏期,抑制TNF-α、IL-1β、IL-6等促炎因子,并下调PI3K/AKT/TRP轴关键调控因子(PI3K、AKT、NF-κB p65、TLR4、STAT3、TRPV1、TRPA1)的表达或磷酸化水平。结论认为克敏胶囊通过抑制PI3K/AKT信号通路活化及TRPA1、TRPV1离子通道活性发挥治疗作用。

要点

  • 克敏胶囊可减少PIC小鼠咳嗽频率并延长咳嗽潜伏期。
  • 克敏胶囊抑制TNF-α、IL-1β、IL-6等促炎因子减轻气道炎症。
  • 机制涉及抑制PI3K/AKT通路及下调TRPV1、TRPA1表达。

核心结论

  • 克敏胶囊通过抑制PI3K/AKT信号通路活化及TRPA1、TRPV1离子通道活性发挥对感染后咳嗽的治疗作用。

研究设计与样本

  • 研究采用UPLC-MS鉴定克敏胶囊主要成分,并结合转录组学、网络药理学与分子对接探索机制。
  • 体内实验以RSV(10^5.5 TCID50/mL)诱导Balb/c小鼠PIC模型,自感染后第14天起以0.3、0.6、1.2 g/kg剂量灌胃给药两周。
  • 体外实验评估克敏胶囊对A549细胞增殖的影响。

主要发现

  • 克敏胶囊的潜在活性成分为脱氧穿心莲内酯、槲皮素和金圣草黄素。
  • 体内实验显示克敏胶囊显著减少PIC小鼠咳嗽频率并延长咳嗽潜伏期。
  • 克敏胶囊抑制TNF-α、IL-1β、IL-6等促炎因子产生以减轻气道炎症。
  • 小鼠肺组织中PI3K、AKT、NF-κB p65、TLR4、STAT3、TRPV1、TRPA1的表达或磷酸化水平显著降低。

临床怎么用

  • 克敏胶囊作为中药创新药,在PIC治疗中可考虑其抗炎及调控PI3K/AKT/TRP轴的作用机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Kemin capsule (KMC), as an innovative traditional Chinese medicine (TCM), has shown excellent efficacy in treating PIC in China. The post-infectious cough (PIC) is a common condition in pediatrics, and the inflammatory responses to PIC are intricately linked to the immune mechanisms of the host. However, the precise mechanisms involved remain uncertain. AIM OF STUDY: The objective of this research is to investigate the mechanisms by which KMC treats PIC using a combination of UPLC-MS, bioinformatics, network pharmacology, and molecular docking. The study's findings will be corroborated through in vitro and in vivo experiments. MATERIALS AND METHODS: This study identified the main components of KMC using UPLC-MS. The mechanism by which these capsules treat PIC was explored through transcriptomics, network pharmacology, and molecular docking. PIC model in Balb/c mice was induced with respiratory syncytial virus (RSV) at a titer of 10^5.5 TCID50/mL. From day 14 post-infection, the mice were orally administered the capsules at doses of 0.3, 0.6, and 1.2 g/kg for two weeks. Cough was stimulated with capsaicin at 10^-4 mol/mL, and the effects on PIC mice were measured by cough frequency, latency, ELISA, and H&E staining. Expression levels of transient receptor potential (TRP) channel proteins and the PI3K/AKT signaling pathway were analyzed using RT-qPCR, immunohistochemistry (IHC), and western blot (WB). The effect of KMC on A549 cells proliferation in vitro was also assessed. RESULTS: The therapeutic efficacy of KMC is potentially exerted through its inherent bioactive constituents, including deoxyandrographolide, quercetin, and chryseriol. These compounds are hypothesized to modulate the PI3K/AKT signaling pathway and influence the function of TRP channel proteins, consequently mitigating the pathological state associated with PIC. In vivo experiments have demonstrated that KMC significantly reduces the frequency of coughs and extends the cough latency period in mice with PIC. KMC mitigates airway inflammation by suppressing the production of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. The expression or phosphorylation levels of key regulators in the PI3K/AKT/TRP axis in mouse lung tissue, including PI3K, AKT, NF-κB p65, TLR4, STAT3, TRPV1, TRPA1 were significantly reduced. CONCLUSION: KMC exerts its therapeutic effect on PIC by dampening the activation of the PI3K/AKT signaling pathway and the activity of TRPA1 and TRPV1 ion channels.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Yang Z, Liang Y, Wu C, et al. Kemin capsule ameliorates post-infectious cough by modulating the PI3K/AKT signaling pathway and TRPA1/TRPV1 channels. J Ethnopharmacol. 2024. PMID: 39306207. doi:10.1016/j.jep.2024.118837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。